Haleh Bagheri

Haleh Bagheri

Auto-generated profile, based on publicly available information

Haleh Bagheri

Department of Medical and Clinical Pharmacology, Regional Pharmacovigilance Centre of Toulouse, Clinical Investigation Centre 1436, Toulouse University Hospital, 31000 Toulouse, France

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 August 2018 in Expert Opinion on Drug Safety
Verified
Journal Article
Closed access
KNKhac-Dung Nguyen
Khac-Dung Nguyen
BBBahador Bagheri
Bahador Bagheri
HBHaleh Bagheri
Haleh Bagheri
Introduction: Drug-induced bone loss remains the major cause of vertebral and hip fractures and significantly associated to morbidity and mortality. This article will review the common drugs identified as the causes of bone loss and the risk factors and management in European countries. Areas covered: Beyond glucorticoid – the most cause of osteoporosis, many different drugs could cause harmful skeletal disorders. The antiepileptics, hormonal therapy, GnRH antagonists, aromatase inhibitors are well-known cause of bone loss. Osteoporosis and fractures risk also increased with calcineurin inhibitors, antiretroviral drugs, selective inhibitors of serotonin reuptake, loop diuretics, heparins, oral anticoagulants, high doses of thyroxine and proton pump inhibitors. Expert opinion: Drugs are an important secondary cause of osteoporosis. Healthcare professionals should reassess the requirement for drugs and use the lowest dosage and shortest duration. Lifestyle changes, adequate calcium, vitamin D supplement, appropriate monitoring of bone status and initiating osteoporosis treatment if indicated are recommended when drugs having potential deleterious effects on bone are used, particularly in high risk patients. The update and further studies would provide concluded evidences of controversial drugs induced bone loss and determine the best prevention and treatment strategies.

21 October 2013 in Journal of Clinical Pharmacy and Therapeutics
Verified
Journal Article
Closed access
PDF file
MTM. Abou Taam
M. Abou Taam
CRC. Rossard
C. Rossard
LCL. Cantaloube
L. Cantaloube
NBN. Bouscaren
N. Bouscaren
GRG. Roche
G. Roche
HBH. Bagheri
H. Bagheri
Websites and discussion lists on health issues are among the most popular resources on the Web. Use experience reported on social media websites may provide useful information on drugs and their adverse reactions (ADRs). Clear communication on the benefit/harm balance of drugs is important to inform proper use of drugs. Some data have shown that communication (advisories or warnings) is difficult. This study aimed to explore the Internet as a source of data on patients' perception of risk associated with benfluorex and the impact of wider media coverage. Three French websites were selected: Doctissimo, Atoute.org considered the best-known and visited website in France for health questions and Vivelesrondes (Long live the Tubbies) for overweight people. Three periods were chosen: (1) before November 2009 (i.e. before benfluorex withdrawal), (2) between November 2009 and November 2010 (when the risk of valvulopathy with benfluorex appeared in social media) and (3) after November 2010. Two hundred twenty initial postings were analysed. These lead to 660 secondary postings which were analysed separately. In period 1, 114 initial postings were analysed, mostly concerning efficacy of the drug (72%). In period 2, 42 initial postings were analysed involving mainly ADRs or warnings (73%). In period 3, 64 initial postings were analysed; most frequent expressing anger directed at the healthcare system (58%) and anxiety about cardiovascular ADRs (30%). Online consumer postings showed that there were drastic changes in consumers' perceptions following media coverage. This study suggests that analysis of website data can inform on drug ADRs. Social media are important for communicating information on drug ADRs and for assessing consumer behaviour and their risk perception.

16 July 2014 in Drug Safety
Verified
Journal Article
Closed access
PDF file
APArnaud Pagès
Arnaud Pagès
EBEmmanuelle Bondon-Guitton
Emmanuelle Bondon-Guitton
JMJean Louis Montastruc
Jean Louis Montastruc
HBHaleh Bagheri
Haleh Bagheri

10 September 2000 in Fundamental & Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
ELEric Lazartigues
Eric Lazartigues
CBChristine Brefel‐Courbon
Christine Brefel‐Courbon
HBHaleh Bagheri
Haleh Bagheri
SCSandrine Costes
Sandrine Costes
CGClaude Gharib
Claude Gharib
JMJean‐Louis Montastruc
Jean‐Louis Montastruc

17 February 2016 in European Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
LHLaurent Hauviller
Laurent Hauviller
FEFrederic EYVRARD
Frederic EYVRARD
VGValérie Garnault
Valérie Garnault
VRVanessa Rousseau
Vanessa Rousseau
LML. Molinier
L. Molinier
HBHaleh Bagheri
Haleh Bagheri

27 November 2018 in Drug Safety
Verified
Journal Article
Closed access
PDF file
KNKhac-Dung Nguyen
Khac-Dung Nguyen
HNHoang-Anh Nguyen
Hoang-Anh Nguyen
HVHoa Vu
Hoa Vu
TLThi Thuy-Linh Le
Thi Thuy-Linh Le
BDBich-Viet Dang
Bich-Viet Dang
HBHaleh Bagheri
Haleh Bagheri